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A B S T R A C T
This work supports the massive presence of potential immunomodulatory peptides in the human gut metapro-
teome. These peptides were identified through the MAHMI database as potentially anti-inflammatory, and
sixteen of them synthesized for characterize their mechanism of action. From them, peptide HM14 was en-
crypted in an extracellular protein produced by Bifidobacterium longum, a common member of the human mi-
crobiota, and displayed the highest anti-inflammatory capability. Molecular mechanism of action of HM14
pointed to a specific interaction between this immunomodulatory peptide and antigen presenting cells, which
resulted in a higher formation of iTreg cells. Moreover, HM14 was effective in decreasing pro-inflammatory
parameters in PBMCs isolated from a cohort of Crohn’s patients. Finally, non-targeted metabolomics confirmed
the ability of HM14 to modulate the metabolic activity of PBMCs to fulfil its energy and biosynthetic require-
ments. Overall, our combined in silico/multiomics approach supports the human gut metaproteome as a source
for immunomodulatory peptides.
1. Introduction
The human gastrointestinal tract (GIT) is quite a complex ecosystem
characterized by a continuous interaction between food, host cells and
billions of microorganisms that are known collectively as the gut mi-
crobiota (Qin et al., 2010; Sonnenburg, 2015). A healthy individual
harbors thousands of microbial species in his/her gut, but surprisingly a
reduced number of Phyla predominate: Bacteroidetes, Firmicutes and
Actinobacteria (Donaldson, Lee, & Mazmanian, 2015). Gut micro-
organisms and humans have coevolved to keep mutually beneficial
relationships, but we are still far from understanding the molecular
mechanisms underlying this mutualism. The ensemble of genes pro-
vided by our gut microbiota is denominated gut metegenome, and
sometimes the term human microbiome (which can refer also to the gut
environment) is used as synonym (Qin et al., 2010). Accounting for
near 10.000.000 unique genes, clearly outnumbering the human
21.306 of protein-coding genes (Salzberg, 2018), our gut bacteria
complement metabolic attributes that are absent in our organism such
us processing of non-digestible nutrients, production of short-chain
fatty acids (SCFAs), vitamins or xenobiotic degradation (Brestoff &
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Artis, 2013). Other beneficial effects attributed to our gut microbiota
include immunomodulation, production of antimicrobial substances,
enhancement of the mucosal barrier function and competition with
enteropathogens for adhesion sites, limiting potential microbial inva-
sions and teaching our immune system to differentiate between bene-
ficial and harmful bacteria. Therefore, and in a healthy situation, mu-
tualism predominates in the human gastrointestinal tract as the main
ecological interaction (Bäckhed, Ley, Sonnenburg, Peterson, & Gordon,
2005).
The issue here is how this catalogue of mutualistic interactions is
achieved and maintained over time. During the last years, it is be-
coming more and more evident that the relative proportions of the
whole collection of microbes colonizing our GIT are critical in de-
termining health or disease (Franzosa et al., 2019). For instance, the
proportion between Firmicutes and Bacteroides appears to be related to
most autoimmune and inflammatory diseases, being lower values of
this ratio observed for instance in Lupus Systemic Erythematosus or
Inflammatory Bowel Disease (IBD) (Kamada, Seo, Chen, & Núñez, 2013;
Manichanh, Borruel, Casellas, & Guarner, 2012). Unravelling what type
of molecular mechanisms explains the beneficial effects promoted by
our gut microbiota is a challenging field for researchers worldwide
(Kamada et al., 2013). Among the different molecules mediating mo-
lecular interactions between microbiota and host, bacterial proteins are
noteworthy (Sánchez, Urdaci, & Margolles, 2010). Extracellular pro-
teins, those that are secreted and released to the bacterial surroundings,
may be able to interact directly with mucosal cells (Ruiz, Hevia,
Bernardo, Margolles, & Sánchez, 2014; Sánchez et al., 2011). Extra-
cellular proteins from intestinal bacteria are known to regulate not only
signaling pathways, but secretion of chemokines, cytokines, anti-bac-
tericidal peptides (defensins), mucus secretion, production of pseudo-
pods by dendritic cells (DCs), rearrangement of the tight-junctions in
epithelial cells, modulation of the immune function and the response of
the gut-associated lymphoid tissue (GALT) cells (Hevia, Delgado,
Sánchez, & Margolles, 2015; Sánchez, Hevia, González, & Margolles,
2015).
Few years ago, our research group demonstrated how a peptide
encrypted in an extracellular protein from Lactobacillus plantarum was
able to drive the immune response of DCs isolated from Ulcerative
Colitis patients towards more regulatory configurations (Bernardo
et al., 2012). In general, extracellular proteins secreted by our gut mi-
crobiota may be cleaved by intestinal proteases, rending peptides that
can present a bioactivity different from that observed in the native
protein, although this point has not been shown in vivo so far. As
proposed by Karelin and colleagues, generation of encrypted peptides
would define a gut-specific peptide pool with key roles for the main-
tenance of gut homeostasis (Karelin, Blishchenko, & Ivanov, 1998).
With this hypothesis in mind, we designed the Mechanism of Action of
the Human Microbiome database (MAHMI. http://www.mahmi.org) in
which a catalog of near 10.000.000 unique proteins generated by the
MetaHit project was digested with the main intestinal proteases and
crossed against a curated database of known immunomodulatory pep-
tides/proteins (Blanco-Míguez, Gutiérrez-Jácome, Fdez-Riverola,
Lourenço, & Sánchez, 2017; Li et al., 2014). Some of these peptides
were synthesized and incubated with peripheral blood mononuclear
cells (PBMCs) in order to understand if they were or not able to induce a
downstream response in the immune cells. Analysis of an 18 cytokine
array revealed that all peptides induced different changes in the cyto-
kine profiles with respect to basal conditions, being two of them able to
induce production of IL-17 and IL-22, the latter related to healing in the
framework of chronic inflammatory settings (Hidalgo-Cantabrana et al.,
2017). Moreover, a combined metatranscriptomics (RNASeq) and me-
tabolomics (GC–MS) approach, based on previous knowledge of our
group (Cambeiro-Pérez et al., 2018), revealed both molecular and
metabolic changes induced by one of these peptides (termed HM14)
that would support an anti-inflammatory molecular mechanism of ac-
tion. Main results are discussed next.
2. Material and methods
2.1. Ethics
Ethics approval for this study (reference code AGL2013-44039-R)
was obtained from the Regional Ethics Committee for Clinical Research
in compliance with the Declaration of Helsinki. Samples used in this
study were obtained from anonymous donors of the regional blood
donation system and from a cohort of Crohn’s Disease patients.
2.2. Peptide identification and bioactivity prediction
Bacterial peptides used in this study were identified through the
MAHMI pipeline (http://www.mahmi.org). Briefly, this pipeline allows
peptide comparison against a knowledge database of anti-proliferative
and immunomodulatory peptides by sequence similarity analysis. In
this case, the protein catalogue created by the METAHIT project (Li
et al., 2014) (http://gigadb.org/dataset/100064), which represents
unique proteins of the whole human gut metaproteome, was digested in
silico and queried against the reference immunomodulatory and anti-
proliferative peptides of the MAHMI database. Those 133 peptides en-
crypted in larger proteins synthesised by intestinal microorganisms
from L. 134 plantarum and B. longum species which bioactive predic-
tion according to the MAHMI 135 score was equal or higher than 75
were retained (De Jesus Oliveira, De Oliveira, & Da Silva Junior, 2019;
Hidalgo-Cantabrana et al., 2017; Wang et al., 2011) (Table 2). Sixteen
peptides were finally selected and synthesised at the GeneCust facilities
(Ellange. Luxemburg).
2.3. Peripheral blood mononuclear cells (PBMCs) isolation
The capability of synthetic bacterial peptides to induce immune
modulation in vitro was assessed using a PBMCs model. PBMCs were
isolated from the buffy coat of 5 healthy donors from the Community
Center for Blood and Tissues of Asturias (Oviedo. Spain) as previously
described (Hidalgo-Cantabrana et al., 2017).
2.4. Isolation of CD4+ T cells and naïve T cells
CD4+ T cells were isolated from the buffy coat of healthy donors
obtained from the Community Center for Blood and Tissues of Asturias
(Oviedo. Spain). In short, 5.0 mL of buffy were diluted with equal vo-
lume of phosphate buffered saline (PBS) and 25 μLmL−1 of
RosetteSepTM Human CD4+ T cell Enrichment Cocktail (Stemcell
Technologies) was added and incubated for 20min. Then 10mL of PBS
with 2.0% FBS was added to the buffy mixture. The 20mL buffy solu-
tion, containing one part of blood and 3 parts of PBS, was added on top
Ficoll-Hypaque for gradient separation to isolate CD4+ T cells at
3.100 rpm, 20min. The CD4+ enrichment cocktail induced the pre-
cipitation of all the cells unless the CD4+ T cells that stay on top when
gradient separation is performed. After gradient separation, CD4+ T
cells were washed twice with PBS at 1.500 rpm, 5min. CD4+ cells were
resuspended in 1.0mL of PBS and counted in Neubauer chamber.
Naïve T cells (CD4+CD25-) were isolated from the CD4+ T cells
using the CD45RA MicroBeads (Milteny Biotec) following manufacturer
instructions.
2.5. In vitro differentiation of induced Treg (iTreg)
The in vitro differentiation of iTreg was performed as previously
described by Fantini, Dominitzki, Rizzo, Neurath, and Becker (2007)).
Briefly, 24 well plate was coated with 1.0 μgmL−1 anti-CD3 antibody in
PBS for 2.0 h at 37 °C. Naïve CD4+CD25- cells were resuspended 2x106
in X-Vivo15 serum free medium with antibiotics and 500 μL were added
to each well, after washing the plate from the anti-CD3 not adhered.
Then, anti-CD28 antibody (2.0 μgmL−1), TGFβ (5.0 ngmL−1) and IL-2
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(100 UmL−1) were used for iTreg differentiation in the presence or
absent of bacterial extracts (50 μgmL−1). Cells were incubated for
5 days at 37 °C with 5.0% CO2.
2.6. Generation of monocyte-derived DCs
PBMCs were obtained from standard buffy-coat preparations from
12 healthy blood donors (Asturian Blood Transfusion Center, Oviedo,
Spain) by centrifugation over Ficoll-Hypaque gradients (Lymphoprep,
Nycomed, Oslo, Norway). Monocytes (CD14+≥ 95%) were isolated
from previously obtained PBMCs by positive selection using magnetic
CD14 MicroBeads and MACS system (Miltenyi). Immature DCs were
obtained by culturing the PBMC fraction in Dutch modified RPMI 1640
(Sigma-Aldrich, Dorset, UK) containing 100 µg/mL penicillin/strepto-
mycin, 2.0 mM L-glutamine, 50mgmL−1 gentamycin (Sigma-Aldrich)
and 10% fetal calf serum (TCS cellworks, Buckingham. UK)] in 48 well
culture dishes for 6 days (37 °C, 5.0% CO2, high humidity),
200 IUmL−1 GM-CSF and 200 IUmL−1 IL-4 were used as differentia-
tion factors. Half of the medium volume was replaced at days 3 and 5.
MoDC differentiation was assessed by flow cytometry by comparing the
percentage of population expressing CD14 and HLA-DR at days 0 and 6
using monoclonal, FITC and PE conjugated antibodies, respectively.
2.7. Co-cultivation of extracellular proteins and PBMCs
PBMCs were cultivated in round bottom 96 wells microplates using
200 μL of the cell suspension described above. Extracellular proteins
were added to a final concentration of 0.1, 1.0 or 10 μgmL−1, based on
previous studies of the immunomodulatory peptide STp (Bernardo
et al., 2012). PBMCs were activated with 100 ngmL−1 of anti-CD3
antibody added to the RPMI medium. For each donor positive (LPS,
1.0 μgmL−1) and negative controls of PBMCs stimulation were in-
cluded. Microplates were incubated for 5 days at 37 °C with 5.0% CO2.
For metabolomics, PBMCs were cultivated in flat bottom 12 wells mi-
croplates (2.5× 107 cells mL−1 per well) accordingly to previous stu-
dies (Cambeiro-Pérez et al., 2018).
2.8. Hematological analysis and immunological phenotyping
For flow cytometry analysis, PBMCs were surface-stained with
Multiset CD3-FITC/CD16+56-PE/CD45-PerCP/CD19-APC Reagent (BD
Biosciences, San Jose, CA, USA), anti-CD4 (PerCP), anti-CD8 (PE or
PerCP), anti-CD45RA (FITC) (Immunostep, Salamanca, Spain), anti-
CCR7 (Alexa Fluor 647), anti-CD28 (APC-H7), anti-CD45RA (APC-H7),
anti-CD4 (PE-Cy), anti-CD27 (PE-Cy), and anti-CD3 (FITC) (BD
Biosciences). To analyze an activated phenotype, cells were stained
with anti-CD3 (APC), anti-CD8 (FITC or PE), anti-CD4 (PerCP), anti-
CD69 (FITC), anti-CD127 (PE), anti-HLA-DR (FITC), and anti-CD25
(APC) (BD Bioscience). One hundred μL of whole blood from each vo-
lunteer was stained with different combinations of labelled monoclonal
antibodies for 20min at room temperature. Samples were red-blood
lysed with FACS Lysing Solution (BD Biosciences), washed in PBS, and
analyzed using CellQuest software in a FACSCanto Cytometer (BD
Biosciences). Appropriate isotype control mAbs were used for marker
settings.
2.9. Activation and proliferation assays
To analyze the activated phenotype, PBMCs (4.0× 106 cells mL−1)
were cultured in the presence and absence of anti-CD3 (1.0 μgmL−1)
(eBioscience), extracellular protein extract from the 20,079 strain
(DSM) and anti-CD3+DSM. Cells were cultured for 18 h and then
stained with anti-CD69 (FITC), anti-CD3 (PerCP), and anti-CD4 or anti-
CD8 (APC) (Immunostep) and analyzed on the cytometer.
For the proliferation assay, PBMCs were resuspended in PBS at a
final concentration of 5–10× 106 cells mL−1 and incubated with
1.5 μM CFSE (Invitrogen, Paisley, Scotland. UK) for 10min at 37 °C
before being washed twice with RPMI 1640 medium containing
2.0×10−3 M L-glutamine and HEPES. Cells were then cultured at
2.0× 106 cells mL−1 in medium, anti-CD3 (1.0 μgmL−1), Pext or anti-
CD3+Pext. The proliferative responses of CD4+ and CD8+ T-lympho-
cytes were analyzed on day 7 after staining with anti-CD3 (PerCP), anti-
CD8 (PE), and anti-CD4 (APC). The cells were analyzed on a BD
FACSCanto flow cytometer.
2.10. Intracytoplasmic staining
PBMCs (4.0×106 cells mL−1) were cultured in the presence and
absence of anti-CD3 (1.0 μgmL−1), DSM and anti-CD3+DSM.
Frequencies of T cells with intracytoplasmic production of IFN-γ, TNF,
IL-17 and IL-10 after 18 h of culture were measured. Cells were surface-
stained with anti-CD3 (PerCP), anti-CD8 (PE), and anti-CD4 (APC) for
30min at room temperature, lysed and fixed with FACS lysing solution,
permeabilized with BD FACS Permeabilizing Solution 2 (Perm II) (BD
Bioscience), and stained with anti-IFN-γ (FITC) (eBiosciences), anti-TNF
(PE) (BD Bioscience), anti-IL-17 (APC) (Biolegend) or anti-IL-10
(Biolegend) for 30min at room temperature. Cells were washed and
resuspended in 1% paraformaldehyde until FACS analysis.
2.11. Cytokine quantification
Cytokines were measured both in plasma and in the supernatant of
cell cultures. After 5 days, supernatant was collected and stored at
−80 °C for multiplexed cytokine analyses. In the case of humans, the
production of 18 different cytokines were quantified using the Th1/
Th2/Th9/Th17/Th22/Treg Cytokine 18-Plex Human ProcartaPlex™
Panel (Affymetrix eBioscience, San Diego, USA) and the Luminex®
xMap Technology equipment following manufacturer’s settings. The
results for each cytokine were represented using box plot diagrams and
differences between peptides were statistically analysed.
2.12. RNA-seq
Fifteen micrograms of total RNA were extracted from 24 different
moDC samples exposed or not to 1.0 µgmL−1 LPS or 10 µgmL−1
HM14, and also from CD4+ cells isolated using magnetic-conjugated
antibodies from PBMCs previously incubated with anti-CD3 or anti-CD3
+ 10 µgmL−1 DSM. In both cases, the RNeasy Mini Kit (QIAGEN) was
used following the manufacturer’s instructions. Total mRNA was se-
quenced in the facilities of GenProbio SRL (http://www.genprobio.
com/) in a HiSeq Illumina System (Illumina, Inc). Preparation of the
libraries, ligation of required adaptors and sequencing was performed
according to the manufacturer indications. Briefly, about 25 million
paired-end reads of 100 nucleotides were obtained for each sample.
Roughly this represented about 2.5× 109 clean bases after application
of quality filtering suggested by Illumina. Filtered RNA data was ex-
ported in FASTq format and was used as input for DEWE (http://www.
sing-group.org/dewe/) (López-Fernández, Blanco-Míguez, Fdez-
Riverola, Sánchez, & Lourenço, 2019). Files corresponding to this study
are available at the European Nucleotide Archive under accession
PRJEB33568.
2.13. Metabolomics
2.13.1. Chemicals, solutions and materials
Standards of DL-norvaline, succinic acid-2.2.3.3-d4, trans-cinnamic-
d7 acid and D-glucose-13C6 used as surrogates, were purchased from
Sigma Aldrich (Madrid, Spain). Standards for Quality Control mix of
external reference standards, D-fructose and glycine, were purchased
from Panreac (Barcelona, Spain); urea from Scharlau (Barcelona,
Spain); L-phenylalanine. nicotinic acid. succinic acid, DL-malic acid,
myo-inositol and L-cysteine from Sigma Aldrich. Each standard was
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prepared at 100mM in water or methanol depending on the solubility
of the chemical. Surrogates and mix of standards working solutions
were prepared in tert-butylhydroquinone, purchased from Sigma
Aldrich, 2.0 g L-1 in methanol at 1.0 mM. These solutions were stored in
amber flasks at −20 °C. In order to correct injection disturbances. two
polychlorinated biphenyls (PCB30 and PCB204), purchased from
Accustandard (New Haven,USA), were used as internal standard (IS).
Saturated Alkane Mixture (C7–C40) and FAME mix solution were ac-
quired from Supelco (Bellefonte, USA) to support the metabolite iden-
tification. Working solutions of n-alkanes and FAMEs mixture was
prepared in acetone at 1.0 mg L-1. For derivatization. N-Methyl-N-tri-
methylsilyl trifluoroacetamide (MSTFA), chlorotrimethylsilane (TMCS)
and pyridine were purchased from Sigma Aldrich. Methoxylamine hy-
drochloride (MeOX) was from Supelco.
2.13.2. PBMCs co-cultivation and quenching extraction
According to previous metabolomics study (Cambeiro-Pérez et al.,
2018), PBMCs were cultivated in flat bottom 12-wells microplates
(2.5× 107 cells mL−1 per well) and subsequently stimulated in culture
with the peptide HM14 (50 µgmL−1) and LPS (1.0 µgmL−1) as positive
control. Negative controls (no stimulus) besides blank samples (with no
cells) were also included for each donor. The microplates were in-
cubated for 48 h at 37 °C with 5.0% CO2. Quenching samples were
obtained as was described before and stored to −80 °C until derivati-
zation process prior to injection by GC-QqQ-MS.
2.13.3. Derivatization
Quenching extracts (400 µL) and standard solutions were reduced to
dryness under a gentle nitrogen stream and then derivatized in two
steps, in order to make compounds with higher boiling points volatilize
enough to be analysed by GC–MS. Firstly, methoxymation was per-
formed by dissolving the dried samples in 100 µL of MeOX (20mgmL−1
in pyridine), then vortexed for 1.0 min and incubated at room tem-
perature for 1 h. Secondly, the samples were silylated by adding 100 µL
MSTFA with 1.0% TMCS and subsequent incubated at 70 °C for 30min.
Finally, derivatized extracts were transferred to vials and spiked with
2.0 µL of IS mix solution (100mg L-1) for GC-QqQ-MS analysis.
2.13.4. Quality control samples
Three different types of Quality Control (QC) samples have been
employed (QC, QC surrogate and QC standard). Biological QC sample,
named as QC, was made by pooling 45 μL from each of analysed sam-
ples. Surrogate standard QC sample, named as QC surrogate, was made
by spiking with surrogate standards to the QC sample. Reference
standard QC sample was prepared with a mix of standards to evaluate
the derivatization process.
2.13.5. GC–MS analysis
Derivatized samples were analysed with an Agilent 7890 gas chro-
matograph coupled to an Agilent 7000C triple quadrupole detector and
to an Agilent 7650C autosampler (Agilent. California. USA) interfaced
to a PC computer running the software Agilent Mass Hunter Data
Acquisition Software (B.08.00 version). Chromatographic separations
were done by using an Agilent HP 5MS capillary column
(30m×0.25mm×0.25 µm). Aliquots of the derivatized samples
(0.5 µL) were injected using a multimode inlet (MMI) equipped with an
Ultra Inert liner with glass wool from Agilent, in the splitless mode and
the injection temperature set to 280 °C. In order to avoid sample cross-
contamination, acetone washing steps were done before and after each
injection as well as sample washes to prevent air bubble formation. The
initial GC oven temperature was 100 °C and was held for 4.0min, after
which the temperature was increased with 4.0 °Cmin−1 to 300 °C and
held then for 1.56min. Helium was used as a carrier gas with a flow
rate of 1.0mLmin−1. The MS was operated in electron impact ioniza-
tion mode at 70 Ev and full scan monitoring mode from m/z 35 to 600.
The transfer line and ionization source temperatures were set to 280 °C.
2.13.6. Metabolomics data processing, metabolite identification and
statistical analysis
GC–MS raw data files (.d files) were evaluated through visual in-
spection of Total ion chromatograms (TICs) in terms of quality of the
analytical batch (sensitivity loss, retention time precision, IS signal)
using the MassHunter Qualitative Analysis B.07.00 (Agilent
Technologies). QC raw data file was imported to MassHunter
Unknowns Analysis Tool B.07.01 (Agilent Technologies) for the gen-
eration of an in-house spectral library for this experiment. The file was
deconvoluted and metabolites putatively identification was performed
by comparison of the mass spectra with NIST 11 (National Institute of
Standards and Technology, 2011) and Fiehn RTL (Agilent Technology)
libraries at 70% similarity index. To substantiate the identification,
both n-alkanes and FAMEs mixtures were analysed during the analy-
tical batch and retention indices were determined. Once the library was
created, all the remaining samples were processed with Unknowns
Analysis Tool for deconvolution and subsequent metabolites identifi-
cation according to the QC in-house spectral library. Then, data were
aligned and normalized prior to statistical analysis, using MassProfiler
Professional B.14.0 (Agilent Technologies). A filter by frequency was
applied to data, retaining those entities which appeared in more than
100% of samples in at least one condition. Statistical significance
analysis using the one way ANOVA with Tukey’s Honest Significance
Difference (HSD) post Hoc test was performed to identify which entities
were responsible for significant differences among groups with a p-
value < 0.05. Fold change cut-off>2.0 was also applied. Hierarchical
clustering was performed by applying Pearson’s uncentered-absolute
distance metric and complete linkage to demonstrate relationships
among groups. Unsupervised principal component analysis (PCA) was
conducted to observe the distribution of samples and QCs; providing
information about sample dispersion and the presence of outliers.
Samples were classified into discrete classes also by supervised Partial
Least Square Discriminant Analysis (PLS-DA).
2.14. Statistical analyses
All experiments were performed in independent biological quintu-
plicates. Data distribution did not follow normality. So initial compar-
isons were performed with the non-parametric Wilcoxon and Tukey
pairwise tests. Differences in the value ranks between two conditions
were assessed with the Mann-Whitney U and Wilcoxon tests for equal
medians with Monte Carlo permutations (n= 99.999) implemented in
the Past3 software v3.15 (Ryan, Hammer, & Harper, 2001). Compar-
isons with a p-value≤ 0.05 were considered statistically significant. All
the graphics showed in this paper were obtained in R environment.
3. Results
3.1. Cytokine profiling in healthy donors using an 18-plex cytokine array.
HM14 is encrypted in an extracellular glycosyl hydrolase family 43
protein (accession WP_013582931) from Bifidobacterium longum. In a
previous study, we established how presence of this peptide modulated
PBMCs immune response using a metabolomics, liquid-chromatography
based approach (Cambeiro-Pérez et al., 2018). For this reason, we
decided to deepen in the knowledge of this mechanism by cytokine
profiling. For such purpose, we incubated this peptide with PBMCs
isolated from healthy donors (n=5) and tested the supernatants using
a Luminex 18-plex cytokine array (Th1/Th2/Th9/Th17/Th22/Treg
Cytokine 18-Plex Human Panel). When we analyzed the increments in
key cytokines as affected by the presence of HM14 or the positive
control LPS, we found that among those cytokines presenting statistical
differences in their production and apart from the anti-inflammatory
cytokine IL-10, HM14 induced statistically significant increments in IL-
4, IL-6, GM-CSF and TNFα, but also in IL-2 (Fig. 1A) (Supplementary
Fig. 1). Other peptides triggered pro-inflammatory settings or anti-
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inflammatory, but not in the extent of that of HM14.
3.2. Data quality assessment of untargeted GC/MS metabolomics
Firstly, we validated our untargeted GC/MS metabolomics approach
to assess the performance of our method with the aim to complement
previous data obtained by LC/MS (Cambeiro-Pérez et al., 2018). Due to
the inexistence of official guidelines for validating untargeted meta-
bolomics, we implemented previously published indications such as
replicated samples, internal standards, Quality Control (QC) samples
and blank samples (Gika, Zisi, Theodoridis, & Wilson, 2016; Naz,
Vallejo, García, & Barbas, 2014; Sangster, Major, Plumb, Wilson, &
Wilson, 2006).
Replicated sample measurement (including biological and technical
replicates) was performed in order to reduce biological and analytical
variability. Moreover, internal standards were added prior injection to
each sample in order to correct instrumental variances.
Three different types of QC samples were employed (named as QC,
QC surrogate and QC standard). QC standard was prepared with a mix
of a representative set of compounds, belonging to different chemical
classes, to evaluate the derivatization process. Derivatization precision
was tested with four different concentrations of the reference standard
mixture in quadruplicate in the same batch and across 7 days, showing
RSDs in the most of cases below 10%. Recoveries of surrogate standards
were measured in all samples ranged from 75 to 104% with
RSDs < 20%. To determine the overall precision of the experiment, QC
and QC surrogate samples were analysed intermittently during the
analytical run every 5 samples, resulting calculated RSDs in all
cases < 10%.
Finally, analytical blanks allowed controlling the correct analytical
method development and identifying background features whilst
method blanks (BQuench samples) allowed identifying the background
related to the entire methodological process from quenching to injec-
tion.
3.3. GC/MS results
After data processing, 102 putatively identified entities were sig-
nificantly differentiated (p-value < 0.050 and fold change>2.0)
among groups. Escherichia coli lipopolysaccharide (LPS) was used as
reference of pro-inflammatory metabolism. Data natural distribution
seemed to be slightly clustered with the QC partially centred between
conditions, as it was reflected through a supervised Partial Least Square
Discriminant Analysis (PLS-DA) 3D score plot (Fig. 1B). In this case,
separation between LPS (light blue circles) and the rest of conditions is
more emphasized. To confirm the possible relationships among sample
groups, a hierarchical clustering analysis was performed by applying
Pearson’s uncentered absolute similarity measure and complete linkage
(Fig. 1C). The dendrogram clusters the four experimental conditions
into three classes, indicating close clustering between HM14 and Basal,
which differed from LPS. These results are concordant with those pre-
viously reported by LC/MS approach (Cambeiro-Pérez et al., 2018).
Finally, 30 metabolites were found overproduced in PBMCs after
incubation with HM14 comparing to basal condition whilst 6
Fig. 1. (A) Increments (treatment vs basal conditions) in cytokine production by PBMCs incubated with HM14 or LPS. (B) PLS-DA 3D score plot, showing an overall
accuracy of the model of 93.3%, R2= 0.673 and Q2= 0.206. (C) Enrichment analysis overview graph. (D) Hierarchical clustering analysis by applying Pearson’s
uncentered absolute similarity measure and complete linkage. Results are expressed as the median of 5 biological replicates. (*** p < 0.05).
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metabolites were found underproduced by HM14. Metabolomic data
interpretation was performed by MetaboAnalyst 4.0 (http://www.
metaboanalysts.ca) through MSEA (metabolite set enrichment ana-
lysis) with over representation analysis (ORA) tool. MSEA allows
identifying the most significant metabolic pathways, based on their p-
values and fold enrichment, included in the SMPDB (Small Molecular
Pathway Database) based on normal human metabolic pathways. In our
case, 68 metabolite sets were found modulated in HM14 condition of
which, 42 were represented by more than 2 metabolites in the pathway
(Fig. 1D). Among them, the most enriched pathways (p-value < 0.050
and FDR < 0.30) were: urea cycle, Glycolysis, gluconeogenesis, nico-
tinate and nicotinamide metabolism, galactose metabolism, Warburg
effect, pyrimidine metabolism, glycerol phosphate shuttle, inositol
phosphate metabolism, cardiolipin biosynthesis, inositol phosphate
metabolism and phosphatidylethanolamine biosynthesis. A complete
list of up and downregulated entities are available in Suppl. File 1.
3.4. Anti-inflammatory effect of HM14 in PBMCs from a Crohńs disease
cohort
Given that HM14 induced metabolic responses compatible with an
anti-inflammatory effect, and given that it promoted IL-10 and IL-2
secretion in PBMCs from healthy donors, we tested the effect of the
peptide in PBMCs isolated from a cohort of Crohn Disease patients
(n=5). The fact that all the patients were sampled at the time of di-
agnosis is very important because it means immune cells were obtained
in the absence of any treatment for IBD. We used the same 18-plex
cytokine array and included another microbiota peptide (LR17), which
was previously reported as Th17/Th22 promoter in a previous study
(Hidalgo-Cantabrana et al., 2017). Globally, HM14 increased produc-
tion of IL-10 and prevented the increase in IL12p70 elicited by the T-
cell activator anti-CD3 antibody, confirming the anti-inflammatory ef-
fect of this Bifidobacterium-derived peptide. LR17 peptide was unable to
reproduce HM14 behavior (Fig. 2; Suppl. File 2).
3.5. Molecular mechanism of action of HM14 over on monocyte-derived
dendritic cells
HM14 was identified through the MAHMI database web-service
(http://www.mahmi.org) which was able to identify im-
munomodulatory peptides. Based on our previous results obtained by
cytokine profiling of bacteria-derived peptides (Bernardo et al., 2012)
and metabolomics (Cambeiro-Pérez et al., 2018) from PBMCs, we fo-
cused our interest in monitoring the influence of HM14 vs. other
MAHMI selected peptides on monocyte-derived dendritic cells
(MoDCs). To confirm the effect of HM14, 15 peptides encrypted in
extracellular proteins of Bifidobacterium longum subsp. longum and
Lactobacillus plantarum, representatives of both probiotic and intestinal
bacteria, including HM14, were incubated with MoDCs from healthy
donors, by cytokine profiling and transcriptomics measurements.
We evaluated the production of anti-inflammatory cytokine IL-10.
Only 4 out of the 15 peptides assayed induced the production of IL-10
by MoDCs when assayed at 10 µgmL−1, the HM14 peptide showing on
of the higher capacities to induce IL-10 secretion (Fig. 3A). Peptides
SP13 and AY14, obtained from the already known anti-inflammatory
molecule STp, were also associated with high IL-10 production. A fur-
ther transcriptomic profiling of MoDCs using RNASeq, revealed that
each of the IL-10-inducing peptides imprinted a particular gene ex-
pression pattern, being that of HM14 the most distant regarding the
pro-inflammatory LPS molecule (Fig. 3B; Suppl. File 3 and 4).
Enrichment analysis (ConsensusPathDB-human; http://cpdb.
molgen.mpg.de/) originated from the transcriptomic data, suggested
that HM14 peptide induced a molecular mechanism of action depen-
dent on Toll-like receptor and NF-kB signaling (Suppl. Fig. 2). A com-
plementary enrichment analysis using the DAVID web-service (https://
david.ncifcrf.gov/), evidenced that many terms and pathways involved
in immunological processes were enriched in MoDCs as affected by the
presence of HM14. Among the genes over-expressed by HM14 we de-
tected several coding for interleukins or interleukin receptors, as well as
markers of dendritic cell maturation and functionality, such as CD83,
CD33 and CD48 (Table 1).
3.6. Molecular mechanism of action of HM14 over CD4 T-cells
As IL-10 and IL-2, two cytokines involved in regulatory T cell (Treg)
expansion, were overproduced in the presence of HM14, we char-
acterized whether this peptide was able to generate Treg cells in vitro
(iTreg) and whether those cells were functional. iTreg cells were rou-
tinely produced from CD4+ naïve cells in the presence of anti-CD3,
anti-CD28, IL-2 and TGF-β. As it can be seen in Fig. 4A, HM14 did not
blocked iTreg cell expansion, and there was a net increase in the % of
iTreg cells (n= 9) compared to basal conditions. These iTreg cells in-
duced the production of IFNγ when co-incubated with naïve CD4+ T-
cells, confirming their functionality, although the proportion of IFNγ
induced in the presence of HM14 was significantly lower than the po-
sitive control (Fig. 4A, B). Finally, HM14 promoted IL-10 secretion by
iTreg in the presence of the polyclonal CD3 activator (Fig. 4C), and no
changes in TGFβ production were noticed (Fig. 4D).
Regarding IL-22 production, we previously noticed a remarkable
but not statistically significant increase in this cytokine in PBMCs from
healthy donors (Suppl. Fig. 1). As IL-22 may also have a healing role in
chronic inflammatory settings, we performed several flow cytometry
experiments with a larger cohort. As previously, presence of HM14 did
not resulted in significant IL-22 production increases (Fig. 5A), but
intracellular IL-22 staining revealed a significant increase in IL-22+
cells (Fig. 5B, C).
Fig. 2. Changes in key cytokines in PBMCs isolated from Crohn’s Disease patients promoted by the incubation of different peptides. In the left panel, presence of
HM14 is increasing IL10 production with respect to basal conditions, whereas in the right panel, the IL12-secreting effect of the polyclonal T-cell activator is
attenuated by the presence of HM14. Both results are in agreement with the anti-inflammatory HM14 effect. Act: CD4+ polyclonal activator. LR17: Th17 pro-
inflammatory peptide.
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4. Discussion
There is solid scientific evidence pointing that certain bacteria
promote mucosal homeostasis favoring the expansion of Treg cells,
increasing the production of anti-inflammatory cytokines and de-
creasing the release of pro-inflammatory cytokines (Ruiz et al., 2014).
Given the anatomic structure of the intestinal mucus layer (Swidsinski
et al., 2007), the existence of a molecular cross-talking between bac-
teria an immune cells through soluble mediators has been proposed
(Sánchez et al., 2010). These soluble mediators derived from probiotic
bacteria would be responsible for molecular cross-talking mechanisms,
supporting beneficial effects over host health; the term postbiotics has
been proposed for these compounds (Tsilingiri & Rescigno, 2013;
Tsilingiri et al., 2012). Currently, we have extended evidence for the
presence of a varied array of molecules and metabolites that, shed from
our intestinal microbiota, alters the immune status after binding to
specific receptors (Maslowski & Mackay, 2011). Therefore, a plausible
hypothesis is that a continuous molecular cross-talking between all the
molecules released by our intestinal microbiota and human host may
determine the immune function during the whole life of an individual.
Ten years ago, we had one of the first evidences of the presence of
an immunomodulatory peptide encoded in an extracellular protein se-
creted by the lactic acid bacterium Lactobacillus plantarum, denomi-
nated ST peptide (Al-Hassi et al., 2014; Bernardo et al., 2012). Notably,
this peptide was patented and it has been approved in the EEUU market
(US9340588B2, https://patents.google.com/patent/US9340588B2/
en). Recently, we moved to the hypothesis of whether the occurrence
of this kind of bioactive peptides was general in probiotic and gut mi-
croorganisms, always in the framework of finding those related to
beneficial effects over the health status of the human host (Blanco-
Míguez et al., 2017; Li et al., 2014). For this purpose, we have chosen
peptides encrypted in the extracellular proteins of Bifidobacterium
longum subsp. longum and Lactobacillus plantarum, as the first is a major
component of the human gut microbiota and the second one a re-
presentative species with many probiotic strains, and also the species
were the ST peptide was discovered, which was shown to modulate the
immune status of both intestinal and MoDCs (Al-Hassi et al., 2014;
Bernardo et al., 2012). We have already discovered several hundreds of
peptides with potential immunomodulatory activity based on the
MAHMI pipeline. Some promoted Th17- or Th22-like cell responses as
deduced from the cytokine profiles induced in DCs, but others, such as a
peptide encrypted in a B. longum subsp. longum extracellular protein,
displayed many tolerogenic properties in the extracellular environment
of human lamina propria mononuclear cells cultures (Fernández-Tomé
et al., 2019; Hidalgo-Cantabrana et al., 2017). Further, we have in silico
evidence for the presence of potential neuroactive peptides also en-
crypted in the intestinal metaproteome (Blanco-Míguez, Fdez-Riverola,
Lourenço, & Sánchez, 2019).
HM14 peptide, which is present in this work, is a novel molecule
able not only to increase IL-10 production in healthy donors and in a
cohort of Crohńs patients, but also able to prevent the increase in the
pro-inflammatory cytokine IL-12 as response to a clonal T-cell acti-
vator. HM14 peptide is therefore an example of the thousands of po-
tential anti-inflammatory peptides that might be generated from our
intestinal microbiota. The fact to have both pro, and anti-inflammatory
peptides released from the gut microbiota is a reflect of the own human
physiology, where many immunomodulatory proteins with opposite
functions are present, such as IL-1β (pro-inflammatory) and IL-10
(regulatory) (Geranurimi et al., 2019). Presence of immunomodulatory
peptides is not only a microbiota property, as several small peptides
encrypted in other proteins such as the human annexin A1 reported
anti-inflammatory activity in animal models of IBD (Cobos et al., 2018);
presence of encrypted immunomodulatory peptides is also described in
food proteins, with strong links related to the maintenance of gut
homeostasis (Fernández-Tomé et al., 2019).
Additional experimental results supported the role of HM14 as an
immunomodulatory peptide. HM14 was able to influence the function
of iTreg cells that, when incubated with naïve T cells, induced them to
produce significantly less IFNγ and a slightly higher amount of IL-10.
The peptide also increased the production of IL-2 in healthy donors. IL-
2 has essential roles in key functions of the immune system, tolerance
and immunity, through a direct effect on T cells. For instance, IL-2 is
central in the differentiation of naïve CD4+T cells into Treg cells, an
immune cell population which is precisely decreased in autoin-
flammatory diseases (Zelante, Fric, Wong, & Ricciardi-Castagnoli,
2012). Effect of HM14 on CD4+T lymphocyte differentiation towards
iTreg was clear. In PBMC cultures, HM14 could be acting on many
cellular types and induces production of many different cytokines. This
makes impossible to analyze its effect on iTregs in this conditions.
RNASeq experiments suggested that HM14 signaled through antigen
presenting cells using innate immune pathways. In this sense hla-dqb1,
hla-dqa1, hla-dra or hla-drb1 genes were over-expressed. All these genes
code for proteins that are part of the peptide-presenting machinery
(usually peptides of 10–30 residues), which is generally referred as the
major histocompatibility complex (MHC) class II. This complex is
mainly expressed in antigen presenting cells, including macrophages
and dendritic cells (Anders et al., 2011); however, epithelial cells from
the gastrointestinal tract, have also been reported to express MHC class
II molecules (Wosen, Mukhopadhyay, MacAubas, & Mellins, 2018); this
is supposed to mediate a kind of non-professional antigen presentation,
with potential implications in immune system-microbiota molecular
crosstalk.
It was also noteworthy the over-expression of the tlr1 gene, as re-
presentative of the Toll-like receptors, which are part of the innate
Fig. 3. (A) Levels of IL-10 (pg mL−1) and (B) global patterns of gene expression profiles induced by different peptides over MoDCs.
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immune system where they recognize microbial associated molecular
patters. Ligand to TLR1 is unknown, although it is known that the
heterodimer with TLR2 recognizes di- and tryacylated lipopeptides
(West et al., 2011). Finally, a number of C-C Motif Chemokine Ligand
and related genes were also overexpressed, such as ccl18 (4796.71-fold)
or ccl2 (842.23-fold). Usually, these ligands display chemotactic ac-
tivity for T cells, but not for other immune cells such as monocytes.
These chemokines participates in the attraction of naïve T cells toward
antigen presenting cells, which is in agreement with the hypothesis that
HM14 is recognized via innate immunity (Krohn, Garin, Gabay, &
Proudfoot, 2013). This was reinforced with the upregulation of genes
coding for dendritic cell maturation markers, such as pdl1, cd40, cd83,
cd80 and cd86. Moreover, genes coding for key intracellular signal
transduction proteins such as jak3, nfkb1 and nfkb2 were also over-
expressed. Finally, overexpression of genes coding for interleukin re-
ceptors involved in Treg cell expansion such as il2rg and il10ra, and
citokines such as il10. The rest of the in vitro experiments, including the
generation of iTreg cells and the anti-inflammatory effect over PBMCs
isolated from IBD patients strongly suggest that HM14 is recognized via
innate immunity, presented to naïve T cells which are further differ-
entiated to Treg.
Non-targeted metabolomics allowed us to understand the impact of
HM14 on metabolic pathways and its implications on the development
and function of PBMCs.
A previous metabolomics research from our group demonstrated a
differential response in cells exposed to HM14 with respect to LPS and
basal condition. Specifically, changes in nicotinate and nicotinamide
metabolism as well as increments in palmitic acid and metanephrine
were observed in HM14 treated-cells (Cambeiro-Pérez et al., 2018).
However, since the analytical platform selected in that previous work
was LC-QTOF-MS, predominant differences were observed in glycer-
ophospholipids metabolism. That is why, in order to cover the largest
number of compounds and their wide range of polarities, which allows
us to know in depth the metabolic state of the cell, GC–MS metabo-
lomics analysis was performed.
This platform not only reinforces the previous knowledge about
changes in nicotinate and nicotinamide metabolism but also reveals
important alterations in aminoacids biosynthesis in HM14 treated-cells,
besides providing valuable information regarding carbohydrate, purine
and pyrimidine metabolism.
Aminoacids are known to play an important role in immune func-
tion by regulating lymphocytes, natural killer cells and macrophages
activation; antibodies and cytokines production; cellular redox state;
gene expression and lymphocyte proliferation (Li, Yin, Li, Woo Kim, &
Wu, 2007). Among them, arginine, glutamine, ornithine, citrulline,
hydroxyproline, serine, tyrosine and alanine were found up-regulated
by HM14 in PBMCs, whilst only proline was found down-regulated.
Glutamine is known to be the major energy substrate for immune cells
as well as to be responsible for regulate lymphocytes proliferation and
glutathione production, crucial for preventing cell oxidative stress,
besides being an essential precursor for the synthesis of purine and
pyrimidine nucleotides (Cruzat, Rogero, Keane, Curi, & Newsholme,
2018). This regulation was also observed in RNASeq experiments were
gls and glul genes, involved in glutamine and glutamate metabolism,
were found overexpressed.
Glutamine is also an important precursor for de novo synthesis of
arginine (Ligthart-melis et al., 2008), which was found up regulated in
HM14 treated-cells as well as their downstream metabolic products,
ornithine and citrulline. Moreover, serine supports de novo purine
nucleotide biosynthesis (Ma et al., 2017), phosphatidylserine and
sphingolipid synthesis and also contributes to nucleotide and redox
metabolism, playing a major role in maintaining mitochondrial meta-
bolism (Gao et al., 2018). Tyrosine is a precursor for catecholamines,
Table 1
Relevant gene expression changes induced by HM14 on monocyte-derived
dendritic cells.
Gene_name Fold change p-value q-value
Receptors
HLA-DQB1 3477.18 0.000 0.004
HLA-DQA1 533.24 0.000 0.003
HLA-DRA 1.47 0.001 0.005
HLA-DRB1 1.42 0.002 0.009
HLA-DMA 1.67 0.001 0.005
HLA-DMB 1.97 0.000 0.003
HLA-DPB1 1.97 0.001 0.008
TLR1 1.69 0.050 0.110
CCL18 4796.71 0.000 0.004
CCL2 842.23 0.001 0.006
CCL13 220.93 0.001 0.005
CXCL8 175.02 0.000 0.004
CCL3 98.45 0.000 0.003
CCL4 72.54 0.000 0.003
CCL7 38.43 0.000 0.004
CCL23 29.06 0.002 0.009
CXCL2 15.97 0.008 0.028
CCL17 5.15 0.000 0.001
Intracellular signal transduction
JAK3 13.05 0.000 0.002
NFKB1 2.80 0.000 0.003
NFKB2 3.70 0.000 0.003
NFKBIA 7.61 0.000 0.003
NFKBID 2.70 0.008 0.028
Interleukin receptors
IL17RB 1350.71 0.000 0.004
IL7R 59.11 0.000 0.003
IL3RA 39.54 0.001 0.007
IL36RN 5.50 0.034 0.082
IL18BP 3.42 0.000 0.005
IL1RAP 1.71 0.004 0.016
IL1RN 2.39 0.002 0.009
IL22RA2 12.90 0.000 0.004
IL2RG 2.90 0.001 0.008
IL10RA 1.29 0.002 0.011
IL21R 1.15 0.043 0.099
IL3RA 8.77 0.038 0.089
Interleukins
IL10 19.80 0.003 0.013
TGFA 5.58 0.000 0.003
IL1A 15.45 0.000 0.003
IL1B 13.00 0.002 0.012
IL4I1 3.14 0.028 0.070
Dendritic cell maturation markers
CD274 (PD-L1) 6.63 0.000 0.002
CD80 6.44 0.000 0.004
CD86 1.17 0.009 0.030
CD83 3.10 0.000 0.002
CD40 2.48 0.002 0.012
Table 2
Peptides used in this study.
Sequence Short name Bacterial species
N-EVNGDSTTTTSTS-C ES13 L. plantarum
N-TQTTQQTTTTQSS-C TS13 L. plantarum
N-AQTSQTQAQPSQA-C AA13 L. plantarum
N-SQTQSSQTQTSKP-C SP13 L. plantarum
N-AAQTTQTSSSTSNY-C AY14 L. plantarum
N-TLAADPVMLTKPEY-C TY14 B. longum subsp. infantis
N-KPRRRRIAAM-C KM10 B. longum subsp. infantis
N-TQSTASGGEPAPADLQSF-C TF18 B. longum subsp. infantis
N-HTEGEAQAIDAPAM-C HM14 B. longum subsp. infantis
N-NTEGIDLTKVGDY-C NY13 B. longum subsp. infantis
N-AEVEGDNNAMLR-C AR12 B. longum subsp. infantis
N-LRFPGGCIVEGVTPGNE-C LE17 B. longum subsp. infantis
N-SEGMHVVDAG-C SG10 B. longum subsp. infantis
N-VSGGTVTLPDDATNV-C VV15 B. longum subsp. infantis
N-YGRSENTGTSN-C YN11 B. longum subsp. infantis
N-TVATGSEEPTAGLPSEGPAD-C TD20 B. longum subsp. infantis
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which regulate immune and inflammatory responses. There are evi-
dence that PBMCs are able to synthesize and breakdown catechola-
mines (Marino et al., 1999). As was previously reported by our LC-MS
metabolomics approach (Cambeiro-Pérez et al., 2018), two metabolites
of catecholamine catabolism showed differences in HM14 treated-cells,
specifically overproduction of metanephrine (breakdown product of
epinephrine) and down regulation of homovanillic acid (break down
product of dopamine). These results were supported by RNAseq data,
that indicated an overexpression of maoa which encodes for the
monoamine oxidase A, key enzyme in catecholamines metabolism.
Tyrosine can be also incorporated into proteins. Phosphorylation and
dephosphorylation of tyrosine residues, modulates protein's function by
triggering an activation or inactivation mechanism of intracellular
signalling molecules (Spalinger, Mccole, Rogler, & Scharl, 2015). The
enzymes responsible for dephosphorylation are protein tyrosine phos-
phatases (PTPs). Among them, protein tyrosine phosphatase non-
Fig. 4. iTreg generation and functionality. (A) Percentage of differentiation of iTreg modulated by the presence of HM14 with respect to normal protocols (+). (B)
On-going production of IFN-γ in CD4+ cells as affected by the presence of iTreg differentiated in the presence (HM14) or absence (+) of the HM14 peptide. (C) and
(D), on-going production of IL-10 and TGF-β by iTreg cells treated with the polyclonal CD4 activator (Act), the peptide HM14 or a combination of both molecules.
Results are expressed as the mean of 5 biological replicates (* p < 0.05** p < 0.01).
Fig. 5. (A) IL-22 production in PBMC fraction treated with LPS, MRS (Control protein extract), polyclonal CD4 activator (Act), the peptide HM14 or a combination of
both. (B) IL-22 percentage of IL-22 positive cells in PBMC fraction treated with LPS, MRS (Control protein extract), polyclonal CD4 activator (Act), the peptide HM14
or a combination of both. (C) Intracitoplasmatic production of IL-22 in CD4+ as affected by the exposure to LPS or HM14 peptide. Results are expressed as the mean
of 5 biological replicates.
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receptor (PTPN) type 2 and type 22 expression levels, are reported to be
altered in actively inflamed intestinal tissue. In fact, PTPN2 knock-out
mice suffer from severe intestinal and systemic inflammation and dis-
play alterations in innate and adaptive immune responses. PTN2 dys-
function increased secretion of pro-inflammatory cytokines, promotes
disruption of the intestinal epithelial barrier, limit autophagosome
formation and contributes to the manifestation of IBD (Spalinger et al.,
2015, 2016). On the other hand, PTPN22 is also involved in controlling
inflammatory signalling in lymphocytes and mononuclear cells, altering
cytokine secretion pattern and autophagosome formation. Deficiencies
in this enzyme, are more severe in colitis, revealing its importance for
intestinal homeostasis in vivo (Spalinger, McCole, Rogler, & Scharl,
2015). Metatranscriptomics analysis suggested that HM14 enhanced
the expression of ptpn2 and ptpn22 coding genes.
Several metabolites involved in nucleotide metabolism were found
up regulated in presence of HM14 in PBMCs; adenosine, hypoxanthine,
cytidine monophosphate, uridine monophosphate and glutamine.
Purine and pyrimidine nucleotides are essential in DNA and RNA
synthesis, crucial for tissue repair, protein synthesis and cell turnover.
Moreover, nucleotides are involved in signal transduction, regulation of
enzyme activity, membrane lipid biosynthesis and protein glycosylation
(Lane & Fan, 2015; Quéméneur et al., 2003). RNAseq also supported the
activation of these metabolic pathways both with the overexpression of
the enzymatic machinery involved in the pathways themselves (ak4;
ak6, prps1, nt5c3a, dck, cmpk1…), and the overexpression of several
polymerases (pole4, polk, polr2f, polr2k, polr2l, polr3f, polr3k), essential
for DNA and RNA biosynthesis. In this way, we are showing using two
different omic technologies, metabolomics and transcriptomics, that
presence of HM14 is triggering nucleic acid biosynthesis, likely related
to an expansion of some of the populations integrating the PBMC
fraction.
Among carbohydrates, glycolytic intermediaries were found up
regulated in HM14 treated-cells such as 3-phosphoglyceric acid, glucose
6-phosphate and dihydroxyacetone phosphate; as it was also observed
in metatranscriptomics analysis with the over-expression of key en-
zymes of glucose metabolism (hk3, pgm2, fbp1, tpi1, bpgm, pgk1, eno1,
dlat). Due to cells rely on glucose for energy, an elevated glycolysis rate
fuels the generation of the precursors required for cellular growth and
proliferation (Shehata et al., 2017).
Generally, metabolomics results suggested that HM14 promotes
protein synthesis through up-regulation of amino acid biosynthesis and
nucleotide metabolism besides encouraging a glycolytic state to fulfil
cell-type-specific metabolic requirements; as maintaining the enzymatic
machinery, cell differentiation and expansion, cytokine production,
signalling mechanisms, among others.
5. Conclusions
To conclude, the human gut metaproteome is source for a vast array
of potential immunomodulatory peptides, that can be identified
through an in silico pipeline. HM14 exerted its anti-inflammatory effect
by acting on a yet uncharacterized innate immune receptor.
Presentation of HM14 to naïve T cells, in vitro, stimulated iTreg ex-
pansion in healthy donors and reduced proinflamatory IL-12 in PBMCs
isolated from Crohn’s patients. In all in vitro settings, HM14 increased
the production of anti-inflammatory IL-10 by immune cells.
Metabolomics analysis also supported a differential behavior between
immune cells exposed to HM14 and untreated cells; suggesting that
HM14 was able to interact with cells and triggers an increase in protein
biosynthesis rate and glycolytic intermediaries. This study opens new
insights directed to the understanding on how these millions of im-
munomodulatory peptides originated from the gut metaproteome affect
the way our microbiota interacts with our immune and potentially with
our nervous system.
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